Notice2026-03517

Notice Pursuant to the National Cooperative Research and Production Act of 1993-Rapid Response Partnership Vehicle

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
February 23, 2026

Issuing agencies

Justice DepartmentAntitrust Division

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 35 (Monday, February 23, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 35 (Monday, February 23, 2026)]
[Notices]
[Page 8529]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-03517]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Rapid Response Partnership Vehicle

    Notice is hereby given that, on October 3, 2025, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership 
Vehicle (``RRPV'') has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Acurx Pharmaceuticals Inc., Staten Island, NY; Advanced 
Concept Innovations, LLC, Lakeland, FL; Altis Biosystems, Inc., Durham, 
NC; Amplitude Therapeutics, Inc., Boston, MA; Ananda Devices, Inc., 
Laval, CANADA; Arizona State University, Tempe, AZ; Arzeda Corp, 
Seattle, WA; Athem LLC, Morrisville, NC; Avocet Bio GmbH, Goettingen, 
FEDERAL REPUBLIC OF GERMANY; Baebies, Inc., Durham, NC; Barupon L.L.C., 
Irvine, CA; Beckman Research Institute of the City of Hope, Duarte, CA; 
Bethyl Laboratories, Inc., Montgomery, TX; BioStrategies LC, Jonesboro, 
AR; Biopico Systems INC, Irvine, CA; Biosynchronicity Corporation, 
Bellevue, WA; Blueprint Biosecurity, Washington, DC; CURA Diagnostics, 
Inc., Woburn, MA; Caci, Inc.--Federal, Chantilly, VA; Cfd Research 
Corporation, Huntsville, AL; Chembio Diagnostic Systems Inc., Medford, 
NY; Curavit Clinical Research Corp, Scarsdale, NY; Curi Bio INC, 
Seattle, WA; Darwin Biosciences, Inc., Broomfield, CO; Diagmetrics 
Inc., Madison, CT; Dlh, LLC, Bethesda, MD; Dnae Group Holdings Limited, 
London, UNITED KINGDOM ; Eitr Biologics, Inc., San Diego, CA; Emerja 
Corporation, Monte Sereno, CA; Enterprise Coding Solutions, LLC, 
Lombard, IL; Evoworks Bio, Cambridge, MA; Exo Imaging, Inc., Santa 
Clara, CA; FOMAT Medical Research, Oxnard, CA; Frontier Bio 
Corporation, Hayward, CA; GCM Pharma, St. Louis, MO; Gerresheimer Glass 
INC, Vineland, NJ; Global Health Investment Corporation, New York, NY; 
Grifols Therapeutics LLC, Research Triangle Park, NC; Hesperos, INC, 
Orlando, FL; Intero Biosystems Inc., Ann Arbor, MI; Jessica Dapelo 
Enterprises INC, Patchogue, NY; Johns Hopkins Center for Health 
Security, Baltimore, MD; Jw3 Biotechnologies LLC, Bothell, WA; Kaleo, 
Inc., Richmond, VA; Kemp Proteins, LLC, Frederick, MD; Kensington 
Street Consulting LLC, Arlington, VA; Lavik Consulting LLC, Oakland, 
MD; Lo Biosciences, Rockville, MD; Martin Blanck & Associates LLC, 
Alexandria, VA; MedMira, Inc., Halifax, CANADA; Methodist Hospital, 
The, Houston, TX; Micromedics INC, Woodland Hills, CA; Mpf Federal, 
LLC, Gaithersburg, MD; Nathe Management Consulting LLC, Austin, TX; 
NeuroAgent AI, Inc., Baltimore, MD; Neuroene Therapeutics INC, 
Kensington, MD; Next Labs, LLC, Rochester, NY; Northstar Emergency 
Management, LLC, Pittsburgh, PA; OmniSpirant Limited, Clonmel, IRELAND; 
Orlance, INC, Seattle, WA; Paratek Pharmaceuticals, INC, Boston, MA; 
Partner Therapeutics, Inc., Lexington, MA; Quantoom Biosciences SA, 
Nivelles, KINGDOM OF BELGIUM; Recourse Biologics, Inc., Houston, TX; 
RenBio, Inc., Long Island City, NY; Rho Federal Systems Division INC, 
Durham, NC; SIGA Technologies, New York, NY; Sagitta Biotech, 
Li[egrave]ge, KINGDOM OF BELGIUM; Sandia Biotech, Inc., Albuquerque, 
NM; Secondcell Bio, New York, NY; Seek Labs, INC, Salt Lake City, UT; 
Sensanna Inc., Hanover, MD; Serodopa Therapeutics INC, Gainesville, FL; 
Ship Odyssey, Inc., Sevierville, TN; Silver Lake Research Corporation, 
Irwindale, CA; Spy Biotech, Ltd., Boston, MA; Synergistic INC, New 
Baltimore, MI; Synvivo INC, Huntsville, AL; THOR Network Foundation, 
Sewickley, PA; Temple University-Of the Commonwealth System of Higher 
Education, Philadelphia, PA; The Charles Stark Draper Laboratory, Inc., 
Cambridge, MA; The Coalition to Stop Flu, Washington, DC; Thorheed 
Titan, Washington, DC; Thylacine Biotherapeutics, Inc., Miami Beach, 
FL; Tissuse Gmbh, Berlin, FEDERAL REPUBLIC OF GERMANY; University of 
Rochester, Rochester, NY; Vasomune Therapeutics INC, Toronto, CANADA; 
Virica Biotech Inc., Ottawa, CANADA; and hVIVO, Inc., Boston, MA; have 
been added as parties to this venture.
    Also, Winsight Consulting LLC, St Michaels, MD has withdrawn as a 
party to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and RRPV intends to file additional 
written notifications disclosing all changes in membership.
    On January 5, 2024, RRPV filed its original notification pursuant 
to section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to section 6(b) of the Act on 
April 16, 2024 (89 FR 26928).
    The last notification was filed with the Department on July 7, 
2025. The Department of Justice published a notice in the Federal 
Register pursuant to section 6(b) of the Act on January 20, 2026 (91 FR 
2370).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2026-03517 Filed 2-20-26; 8:45 am]
BILLING CODE 4410-11-P


</pre></body>
</html>
Indexed from Federal Register on February 23, 2026.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.